We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Imiquimod 5% as Adjuvant Therapy for Incompletely Excised Infiltrative Nodular Basal Cell Carcinoma and Dermoscopy to Monitor Treatment Response.
- Authors
Roldán-Marín, Rodrigo; Toussaint-Caire, Sonia
- Abstract
Introduction: A relatively novel application for dermoscopy is its use in the monitoring of topical treatment response for non-melanoma skin cancer. Basal cell carcinoma (BCC) is the most frequent type of skin cancer in humans. Surgical excision is still considered the 'gold-standard' of treatment. However, a number of topical therapies are now available for the treatment of different types of basal cell carcinoma. Case Report: This case report exemplifies the usefulness of dermoscopy in the monitoring of residual disease after incomplete surgical excision and also in the monitoring of topical treatment response. Imiquimod 5% cream acts as a topical immune response modifier promoting a Th-1 immune response enhancing the removal of neoplastic cells and has proven to reduce deregulated Hedgehog (HH)/GLI signal strength independent of Toll-like receptor signaling, which makes it a valuable adjuvant topical therapy for the treatment of basal cell carcinoma. Conclusion: Imiquimod 5% cream is a valuable adjuvant therapy for the treatment of incompletely excised BCC. This case report adds further evidence to the usefulness of dermoscopy in the assessment and monitoring of treatment outcome.
- Publication
Dermatology & Therapy, 2015, Vol 5, Issue 4, p265
- ISSN
2193-8210
- Publication type
Article
- DOI
10.1007/s13555-015-0088-z